VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the “Company” or “Rakovina”), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that its board of directors has approved the grant of an aggregate of 540,000 stock options (the “Options”) to certain consultants, employees, officers and directors of the Company pursuant to the Company’s Long Term Incentive Plan.
WESTFORD, Mass., July 28, 2025 /PRNewswire/ -- SkyQuest Technology Consulting published a report, titled, Data Center Market- Global Opportunity Analysis and Industry Forecast, 2025-2032",...
Edwin Naranjo Sierra Promoted to VP of Exploration; Mark Gibson Appointed to Board of Directors and Joey Wilkins Joins as Strategic Advisor
VANCOUVER, BC, July...
VANCOUVER, BC, July 28, 2025 /CNW/ - Defense Metals Corp. ("Defense Metals" or the "Company" (TSXV: DEFN) (OTCQB: DFMTF) (FSE: 35D) announces that it has...
VANCOUVER, BC, July 28, 2025 /PRNewswire/ - Defense Metals Corp. ("Defense Metals" or the "Company" (TSXV: DEFN) (OTCQB: DFMTF) (FSE: 35D) announces that it has...
KUALA LUMPUR, Malaysia, July 25, 2025 /PRNewswire/ -- What does it take to succeed in a business world defined by rapid change, digital breakthroughs,...
CALGARY, Alberta, July 24, 2025 (GLOBE NEWSWIRE) -- Athabasca Oil Corporation (TSX: ATH) (“Athabasca” or the “Company”) is pleased to report its second quarter results marked by strong operational performance, consistent financial results and execution on return of capital commitments. With low corporate break-evens, differentiated long-life assets and a pristine balance sheet, the Company is well positioned to advance its strategic priorities.